(Q48788230)

15 February 2018

title

L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. (English)

1 reference

15 February 2018

1 reference

3

Quirion R

1 reference

15 February 2018

author name string

Thiffault C

series ordinal

1

1 reference

15 February 2018

Lamarre-Théroux L

series ordinal

2

1 reference

15 February 2018

Poirier J

series ordinal

4

1 reference

15 February 2018

publication date

1 March 1997

1 reference

15 February 2018

published in

Molecular Brain Research

1 reference

15 February 2018

volume

44

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

238-244

1 reference

15 February 2018

Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The functional role of monoamine oxidases A and B in the mammalian central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

(?)-Deprenyl can induce soluble superoxide dismutase in rat striata

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The molecular pharmacology of L-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Combined in situ hybridization and immunocytochemistry in the assay of pharmacological effects on tyrosine hydroxylase mRNA concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Determination of monoamines in brain nuclei by high performance liquid chromatography with electrochemical detection : Young vs. middle aged rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Effect of MPTP and l‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-328X%2896%2900203-3

7 January 2021

10.1016/S0169-328X(96)00203-3

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018